Antonio Tapia-Galisteo

Antonio Tapia-Galisteo

Auto-generated profile, based on publicly available information

Antonio Tapia-Galisteo

Cancer Immunotherapy Unit (UNICA) Department of Immunology Hospital Universitario 12 de Octubre Madrid Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMarta Compte
Marta Compte
SHSeandean Lykke Harwood
Seandean Lykke Harwood
IMInes G. Muñoz
Ines G. Muñoz
RNRocio Navarro
Rocio Navarro
MZManuela Zonca
Manuela Zonca
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8N/CEGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8N/CEGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy.

7 February 2022 in OncoImmunology
Verified
Journal Article
Open access
ATAntonio Tapia-Galisteo
Antonio Tapia-Galisteo
ÍRÍñigo Sánchez Rodríguez
Íñigo Sánchez Rodríguez
OAOscar Aguilar-Sopeña
Oscar Aguilar-Sopeña
SHSeandean Lykke Harwood
Seandean Lykke Harwood
JNJavier Narbona
Javier Narbona
LSLaura Sanz
Laura Sanz
Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement of their efficacy and selectivity for solid tumors is still required. Here, we describe a novel tandem T-cell recruiting trispecific antibody for the treatment of colorectal cancer (CRC). This construct, termed trispecific T-cell engager (TriTE), consists of a CD3-specific single-chain Fv (scFv) flanked by anti-epidermal growth factor receptor (EGFR) and anti-epithelial cell adhesion molecule (EpCAM) single-domain VHH antibodies. The TriTE was well expressed in mammalian and yeast cells, bound the cognate antigens of the three parental antibodies, and enabled the specific cytolysis of EGFR- and/or EpCAM-expressing cancer cells, without inducing T cell activation and cytoxicity against double-negative (EGFR−EpCAM−) cancer cells. Bivalent bispecific targeting of double-positive HCT116 cells by TriTE improved in vitro potency up to 100-fold compared to single-positive cells and significantly prolonged survival in vivo. In addition, it was less efficient at killing single-positive target cells than the corresponding bispecific controls, leading to potentially enhanced tumor specificity. Moreover, dual targeting of two tumor-associated antigens may contribute toward preventing the tumor escape by antigen loss caused by selective pressures from conventional single-targeting T-cell engagers, and may help to overcome antigenic heterogeneity.

14 February 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
LDLaura Díez-Alonso
Laura Díez-Alonso
AFAïda Falgas
Aïda Falgas
JAJavier Arroyo-Ródenas
Javier Arroyo-Ródenas
PRPaola A. Romencín
Paola A. Romencín
AMAlba Martínez
Alba Martínez
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
Multiple myeloma is the second most common hematological malignancy in adults and remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy, including T cells bearing chimeric antigen receptors (CARs) and systemically injected bispecific T cell engagers (TCEs), has shown remarkable clinical activity, and several products have received market approval. However, despite promising results, most patients eventually become refractory and relapse, highlighting the need for alternative strategies. Engineered T cells secreting TCE antibodies (STAb) represent a promising strategy that combines the advantages of adoptive cell therapies and bispecific antibodies. Here, we undertook a comprehensive preclinical study comparing the therapeutic potential of T cells either expressing second-generation anti-BCMA CARs (CAR-T) or secreting BCMAxCD3 TCEs (STAb-T) in a T cell–limiting experimental setting mimicking the conditions found in patients with relapsed/refractory multiple myeloma. STAb-T cells recruited T cell activity at extremely low effector-to-target ratios and were resistant to inhibition mediated by soluble BCMA released from the cell surface, resulting in enhanced cytotoxic responses and prevention of immune escape of multiple myeloma cells in vitro. These advantages led to robust expansion and persistence of STAb-T cells in vivo, generating long-lived memory BCMA-specific responses that could control multiple myeloma progression in xenograft models, outperforming traditional CAR-T cells. These promising preclinical results encourage clinical testing of the BCMA-STAb-T cell approach in relapsed/refractory multiple myeloma.

13 April 2024 in OncoImmunology
Verified
Journal Article
Open access
ATAntonio Tapia-Galisteo
Antonio Tapia-Galisteo
ISIñigo Sánchez-Rodríguez
Iñigo Sánchez-Rodríguez
JNJavier Narbona
Javier Narbona
PIPatricia Iglesias-Hernández
Patricia Iglesias-Hernández
SASaray Aragón-García
Saray Aragón-García
LSLaura Sanz
Laura Sanz
Immunotherapy has revolutionized cancer treatment landscape, boosting strong antitumoral responses in patients with advanced tumors. However, the success of immunotherapy in solid tumors has been m...

24 April 2023 in OncoImmunology
Verified
Journal Article
Open access
LRLaura Rubio-Pérez
Laura Rubio-Pérez
RLRodrigo Lázaro-Gorines
Rodrigo Lázaro-Gorines
SHSeandean L. Harwood
Seandean L. Harwood
MCMarta Compte
Marta Compte
RNRocío Navarro
Rocío Navarro
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates are urgently needed. New bispecific antibody (bsAb) formats combining the ICB effect and a direct action on cancer cells could improve the efficacy of current immunotherapies. Here, we report the development of a PD-L1/EGFR symmetric bsAb by fusing a dual-targeting tandem trimmer body with the human IgG1 hinge and Fc regions. The bsAb was characterized in vitro and the antitumor efficacy was evaluated in humanized mice bearing xenografts of aggressive triple-negative breast cancer and lung cancer. The IgG-like hexavalent bsAb, designated IgTT-1E, was able to simultaneously bind both EGFR and PD-L1 antigens, inhibit EGF-mediated proliferation, effectively block PD-1/PD-L1 interaction, and induce strong antigen-specific antibody-dependent cellular cytotoxicity activity in vitro. Potent therapeutic efficacies of IgTT-1E in two different humanized mouse models were observed, where tumor growth control was associated with a significantly increased proportion of CD8+ T cells. These results support the development of IgTT-1E for the treatment of EGFR+ cancers.

24 August 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
SLSusana Luengo‐Arias
Susana Luengo‐Arias
CDCarmen Domínguez‐Alonso
Carmen Domínguez‐Alonso
IZIvana Zagorac
Ivana Zagorac
ATAntonio Tapia‐Galisteo
Antonio Tapia‐Galisteo
EGEva García‐Veros
Eva García‐Veros
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
Living cell therapies lack robust, reversible mechanisms for externally controlling therapeutic activity after administration, limiting their safety and clinical adaptability. Here we engineer a drug‐gated cellular immunotherapy platform in which T cells function as programmable factories that secrete two inactive antibody modules whose extracellular assembly into a functional bispecific T cell engager (TCE) is controlled by a small‐molecule input. Using a rapalog‐inducible FKBP‐FRB* heterodimerization switch, we design a split CD19 × CD3 engager architecture that remains inactive in the absence of drug and assembles on demand upon rapalog exposure. A 2A‐peptide bicistronic construct enables coordinated expression and secretion of both modules, allowing precise drug‐dependent control of TCE formation in situ. Drug administration quantitatively regulates T cell activation and cytotoxicity against CD19 + targets in vitro, with stringent OFF‐state behavior in the absence of rapalog. In xenograft models, systemic rapalog administration induces on‐demand anti‐tumor activity without evidence of treatment‐related toxicity, demonstrating reversible pharmacological control of a locally secreted therapeutic interface. We further extend this strategy to an EGFR‐targeting TCE, demonstrating the modularity and broad adaptability of the platform across distinct antigen specificities. This work introduces a generalizable engineering framework for externally programmable cell therapies, enabling tunable, safety‐by‐design control of T cell‐based immunotherapies.